We have previously reported that the downregulation of MMP-2 by adenovirus-mediated delivery of MMP-2 siRNA (Ad-MMP-2) reduced spheroid invasion and angiogenesis in vitro, and, metastasis and tumor growth in vivo. In this study, we investigated the mechanism of Ad-MMP-2-mediated growth inhibition in vitro and in vivo. Ad-MMP-2 infection led to the induction of apoptosis as determined by TUNEL assay, Annexin-V staining and PARP-1 cleavage in a dose-dependent manner in A549 cells. Ad-MMP-2 decreased the content of the antiapoptotic members of the Bcl-2 family proteins (Bcl-2 and Bcl-xL) and increased the content of the proapoptotic members of the Bcl-2 family (Bax and Bcl-xS) as determined by immunoblotting analysis. Furthermore, Ad-MMP-2-mediated apoptosis was accompanied by increase in truncated Bid, release of cytochrome c and the activation of caspase-8, -9 and -3. Immunoblot analysis showed that Ad-MMP-2 infection caused upregulation of Fas/Fas-L and FADD, and Anti-Fas-L antibody reversed Ad-MMP-2-induced apoptosis. Tissue inhibitor of metalloproteinases (TIMP)-3, an endogenous inhibitor of MMP-2, which cleaves Fas-L and activates the Fas/Fas-L inducing apoptotic pathway, was increased in Ad-MMP-2-treated cells. Adenovirus-mediated expression of MMP-2 siRNA in human lung xenografts in vivo resulted in increased immunostaining of Fas, Fas-L, cleaved Bid and TIMP-3. This is the first report, to our knowledge, showing that MMP-2 inhibition upregulates TIMP-3 levels, which in turn, promotes apoptosis in lung cancer.
Introduction
The matrix metalloproteinases (MMPs) consist of a large family of enzymes that, in combination, can digest components of the extracellular matrix (Birkedal-Hansen et al., 1993) . MMP-2 (gelatinase-A) and MMP-9 (gelatinase-B) are the specific MMPs correlated most commonly with breast, ovarian, colorectal and lung cancer growth (Brown and Giavazzi, 1995; Cawston, 1995) . The activity of MMPs is specifically inhibited by tissue inhibitor of metalloproteinases (TIMPs), which binds to active MMPs in a 1:1molar stoichiometry (Brew et al., 2000) . Given the ability of TIMPs to inhibit the proteolytic activity of MMPs, it is not surprising to find that TIMPs are capable of blocking tumor metastasis, either by inhibiting tumor invasion of basement membrane or by restraining tumor angiogenesis (Gomez et al., 1997) . However, recent studies have suggested that the inhibitory effects of TIMPs on tumor progression are not only due to their ability to inhibit MMP activity, but also because of their ability to modulate directly the cell growth and apoptosis of tumor cells, as well as host endothelial cells. High levels of TIMP-3 promote apoptosis in many cell types in vitro and in vivo (Baker et al., 1998; Bond et al., 2000) , this effect is associated with death receptor modulation (Bond et al., 2002) .
It is well established that uncontrolled cellular growth, which occurs as a consequence of defects in cell cycle and apoptotic machinery, is responsible for the development of most of the cancers including lung cancer. Therefore, those agents that can modulate apoptosis in cancer cells may be able to affect the steady-state cell population and be useful in the management and therapy of cancer. Some studies have reported that MMPs promote tumor growth by releasing growth factors from their inactive membrane-bound form (Haro et al., 2000) , thereby suggesting that MMP antagonists would inhibit cell growth. On the other hand, different studies have reported that MMPIs inhibit tumor proliferation by inducing apoptosis via the release of ligands such as TRAIL and TNFa from their membrane-bound inactive forms (Nyormoi et al., 2003) . In a previous study, we demonstrated that adenoviral-mediated siRNA delivery of MMP-2 inhibited lung cancer growth and metastasis (Chetty et al., 2006) . However, the inhibitory mechanism in tumor inhibition in vivo can only be partly explained by the inhibition of the catalytic activity of MMP-2 overexpressed in cancerous tissue. Therefore, we hypothesized that Ad-MMP-2-mediated tumor growth inhibition is mediated by cell growth arrest or apoptosis. In the present study, we demonstrate that Ad-MMP-2 infection induced apoptosis in A549 cells. MMP-2 downregulation induced cytochrome c release, cleavages of caspase-8, -9 and -3 and PARP-1 and DNA fragmentation by the Fas-mediated signaling pathway in A549 cells and A549-grafted tumors in SCID mice. In addition, we show that TIMP-3 is overexpressed with Ad-MMP-2 infection in A549 cells and tumors. Taken together, these results show that TIMP-3 promotes Fas/ Fas-L-mediated apoptosis in lung cancer cells in culture and in vivo.
Results

Ad-MMP-2 induces apoptosis in A549 cells
We have shown previously that downregulation of MMP-2 with Ad-MMP-2 siRNA reduced invasion, migration and angiogenesis in A549 cells in vitro and inhibited tumor growth and lung metastasis in vivo (Chetty et al., 2006) . We have clearly demonstrated the specificity of this virus in our earlier published results and showed that the virus does not activate components of the interferon system. To characterize further the specificity of Ad-MMP-2 infection we determined the expression of other MMP family proteins, MMP-1, -7 and -9. We did not observe any change in the expression of MMP-1, -7 and -9 in Ad-MMP-2-infected cells compared to mock (PBS) and scrambled vector (Ad-SV) controls (Figure 1a ). Of interest, Ad-MMP-2-infected cells displayed morphological signs of apoptosis including cell shrinkage, membrane blebbing and eventual disintegration into numerous apoptotic bodies within 48À72 h of treatment (data not shown). To confirm these initial observations, we analysed apoptosis by looking for phosphatidylserine externalization by annexin-V binding and DNA fragmentation (TUNEL) assay. To quantify early and late events in the course of apoptosis, A549 cells were stained with annexin-V-FITC, 36 h after Ad-MMP-2 infection. As depicted in Figure 1 , infection of A549 cells with Ad-MMP-2-induced annexin-V expression on the cell surface as compared to mock and Ad-SV controls. We observed a dose-dependent increase in annexin-V-positive staining with increasing multiplicity of infection (MOI) of Ad-MMP-2 infection (Figure 1b) . At 48 h post-infection, TUNEL-positive, apoptotic lung cancer cells were meagerly present in mock or Ad-SV-infected cells. Ad-MMP-2 infection resulted in a distinct increase of TUNEL-positive cells in a dose-dependent manner (Figure 1c) . Quantitation of TUNEL-positive cells indicated that at 25 and 50 MOI Ad-MMP-2, 30 and 43% of the cells were TUNEL-positive, and at 100 MOI of Ad-MMP-2, more than 65% of cells were TUNELpositive (Figure 1d ).
Ad-MMP-2 infection alters Bax/Bcl-2 expression and induces cleavage of caspase-3, -8 and -9 and PARP-1 Since Bax and Bcl-2 play crucial roles in apoptosis, we next determined the effect of Ad-MMP-2 infection on protein levels of Bax and Bcl-2 in A549 cells. The immunoblot results exhibited a dose-dependent increase in the expression of the pro-apoptotic protein Bax in cells infected with Ad-MMP-2. In contrast, the protein expression of Bcl-2 was significantly decreased with Ad-MMP-2 infection in a dose-dependent fashion. We observed decreased expression of the antiapoptotic molecules Bcl-xL and increased expression of the proapoptotic molecule Bcl-xs in Ad-MMP-2-treated cells (Figure 2a ). The densitometric analysis revealed an increase in the Bax/Bcl2 and Bax/Bcl-xL ratio in a dosedependent manner (Figure 2b ). Because the alteration in Bax/Bcl-2 is known to initiate caspase signaling, we evaluated the involvement of various caspases in Ad-MMP-2-mediated apoptosis in A549 cells. Figure 2a indicates that Ad-MMP-2 infection induced the cleavage of initiator pro-caspase-8 and -9, and the effector procaspase-3 in a dose-dependent manner. We observed no cleavage of these caspases in the mock and Ad-SV controls. We also found that Ad-MMP-2 infection caused cleavage of the PARP' a downstream effector of caspases. As shown in Figure 2a , the 85-kDa cleaved fragment of PARP-1 was detected in Ad-MMP-2-treated cells, but not in mock and Ad-SV-infected cells.
Ad-MMP-2 induces cleavage of Bid and cytochrome c release Truncated Bid can interact with Bax and enhance its translocation into mitochondria, which, in turn, results in cytochrome c release from mitochondria. Cytochrome c release is the limiting factor in caspase-9 activation and represents a central co-ordinating step in the formation of the apoptosome to induce apoptosis via the mitochondrial pathway (Li et al., 1997) . Therefore, Ad-MMP-2 infection was tested for its ability to cleave Bid and release cytochrome c. As shown in Figure 2c , truncated Bid (p13 and p15) increased with Ad-MMP-2 infection in a dose-dependent manner. Cytochrome c was undetectable in the cytosolic fractions of mock and Ad-SV-infected cells. However, cytochrome c expression was detected even at 10 MOI of Ad-MMP-2 and increased in a dose-dependent manner ( Figure 2c ). Ad-MMP-2 infection increases expression of TIMP-3 TIMP-3 is one of the endogenous inhibitors for MMP-2 and is a secreted 24-kDa protein that, unlike other TIMP family members, binds to the extracellular matrix and induces apoptosis via the Fas/Fas-L system (Baker et al., 1999) (Figure 4 ). We detected both the nonglycosylated and glycosylated-TIMP-3 forms in immunoblot analysis in Ad-MMP-2-treated cells. The non-glycosylated form of TIMP-3 was increased six times in Ad-MMP-2-infected cells (Figures 5a and b) . Cytoplasmic immunoreactivity to TIMP-3 was also significantly increased with Ad-MMP-2 infection (Figure 5c ).
Tumor regression induced by Ad-MMP-2 treatment is due to apoptosis To determine if anti-tumor effect was elicited by apoptosis, we sectioned the tumors for histological and TUNEL analyses. As shown in Figure 6a , very few MMP-2 and TIMP-3 in lung cancer C Chetty et al TUNEL-positive cells were present in the tumors from mice that received mock and Ad-SV treatment. The apoptotic index of the tumor cells quantified by the number of TUNEL-positive cells per field were 25-fold higher in tumors from mice that received Ad-MMP-2 treatment compared to controls. Moreover, the immunoblot analysis of the tumor tissue samples showed that the proforms of caspase-8, -9, -3 and the antiapoptotic molecule Bcl-xL were reduced in tumors from mice that received Ad-MMP-2 treatment. Predictably, the cleaved fraction of PARP (85 kDa) was increased in Ad-MMP-2-treated cells (Figure 6c ). Immunohistochemical analysis of the sections of tumors from mice that received Ad-MMP-2 treatment indicated increased staining for TIMP-3, Bid, Fas-L and Fas compared to mock and Ad-SV controls (Figure 6d ).
Discussion
The present study was designed to define the mechanism(s) underlying the antiproliferative and pro-apoptotic effects of an adenovirus carrying siRNA against MMP-2 (Ad-MMP-2) in the A549 lung cancer cell line. In this study, we provide evidence that adenoviral-mediated delivery of siRNA against the human MMP-2 gene had a direct apoptosis-inducing effect on A549 lung cancer cells. Ad-MMP-2 infection increased Fas and Fas-L, which, in turn, leads to upregulation of the Bax/BCl-2 ratio and activates caspases resulting in the induction of apoptosis. Our results include annexin-V-positive staining, DNA fragmentation and cleavage of PARP-1, which are all indicators of apoptosis. We also observed a decrease in Bcl-2 protein expression, an upstream In addition to degrading ECM components, MMPs are shown to confer apoptosis resistance by modulating Fas-mediated death signaling (Mitsiades et al., 2001) . Decreased sensitivity to Fas-L-mediated apoptosis is a common trait shared by many different types of cancer MMP-2 and TIMP-3 in lung cancer C Chetty et al cells, which provides cancer cells with critical survival advantages that ultimately lead to malignant progression (Khong and Restifo, 2002) . Patient survival analysis revealed that the patients with negative Fas stage-III NSCLC tumors have a worse prognosis (Uramoto et al., 1999) . This fact may indicate that Fas-mediated apoptosis inhibits tumor progression especially in advanced lung cancer patients. Our studies demonstrate that Fas and Fas-L expression increased significantly with Ad-MMP-2 treatment. Other studies have shown that cleavage of Fas by MMP-2 results in decreased sensitivity of HT-29 colon carcinoma cells to Fas-mediated apoptosis (Strand et al., 2004) . Next, to determine whether Ad-MMP-2 affects death signaling downstream of the receptor-ligand interaction, we examined caspase activation. Two major pathways of caspase cascade activation have been characterized. One is initiated by ligation of death receptors and the activation of caspase-8. Caspase-8 is activated by the Fas/Fas-L signal, resulting in the caspase cascade (Medema et al., 1997) . Two pathways are regulated by caspase-8 (Scaffidi et al., 1998) . In one, pro-caspase-3 is directly cleaved by the active form of caspase-8 and transmits apoptotic signals by degrading target molecules. In the other pathway, caspase-8 degrades Bid, a member of the Bcl-2 family. The carboxyl fragment of Bid acts as an input signal to the mitochondria and is transported from the cytosol to the mitochondria where it induces the translocation of cytochrome c (Luo et al., 1998) . Next, cytochrome c associated with Apaf-1, and pro-caspase-9 activates caspase-9 and -3 (Hengartner, 2000) . Therefore, activated caspase-8 can switch on both the death receptor pathway and the mitochondrial pathway via Bid degradation. The results of the present study clearly show increased activity of caspase-3, -8 and -9 as well as Bid degradation and cytochrome c translocation from the mitochondria membrane into the cytosol of A549 cells after Ad-MMP-2 infection. These findings indicate that both the mitochondrial and death receptor pathways are involved in apoptosis mediated by MMP-2 inhibition. To determine further the order of caspase activation, we treated the cells with caspase inhibitors before Ad-MMP-2 infection. Our results indicated that caspase-8 activity was required for caspase-9 cleavage. However, the caspase-9 inhibitor did not have any effect on caspase-8 cleavage (see Supplementary material). These results suggest that the Ad-MMP-2-induced apoptosis functions via the extrinsic II pathway.
MMPs and their endogenous inhibitors (TIMPs) are also involved in modulating cell surface receptors for signaling molecules. A549 cells showed a dramatic increase in non-glycosylated form of TIMP-3 with Ad-MMP-2, which was shown to induce apoptosis (Drynda et al., 2005) . The cell-death domain of TIMP-3 has been localized to the N terminus and its apoptotic effect appears to correlate with the inhibition of metalloproteinase activity (Bond et al., 2000) . Several studies indicate that the loss of TIMP-3 in the tumor cell is an important event during tumorigenesis. Lack of TIMP-3 leads to an early unscheduled activation of MMP-2 and greater matrix degradation (Fata et al., 2001) . Overexpression of TIMP-3 has been shown to restrict tumor cell invasiveness in vitro (Baker et al., 1999) and to inhibit tumor growth in vivo (Spurbeck et al., 2002) . TIMP-3 silencing through promoter methylation is often found in gastric cancer (Kang et al., 2000) . Recombinant TIMP-3 induces apoptosis in melanoma cell lines in vivo by a mechanism that directly involves stabilization of death receptors, including Fas-L (Ahonen et al., 2002). Our studies show that Ad-MMP-2 infection induces TIMP-3 expression resulting in apoptosis by a mechanism that involves increased expression of Fas and Fas-L. Quantitative analysis of Fas-L expression on the cell surface and sFas-L indicated that Ad-MMP-2 infection resulted in a dose-dependent increase in membrane-bound Fas-L and sFas-L, both of which can activate Fas (Tanaka et al., 1995) .
In summary, we have provided evidence here that RNAi-mediated MMP-2 inhibition reduces tumor growth occurs as a result of apoptotic induction. Our data also indicate that inhibition of MMP-2 leads to accumulation of TIMP-3, which, in turn, results in the upregulation of Fas and Fas-L followed by the induction of the pro-apoptotic genes Bax and Bcl-xs. In addition, caspase-8 activation precedes caspase-9 activation, which leads to subsequent apoptotic events, including cytochrome c release and caspase-3 activation MMP-2 and TIMP-3 in lung cancer C Chetty et al in A549 cells. Furthermore, our data demonstrate that a similar pathway functions in the animal model. One possible mechanism of TIMP-3 upregulation in our study could be due to increased phosphorylation of ERK and JNK (data not shown) with Ad-MMP-2 as TIMP-3 induction was shown to be mediated by tyrosine and MAP kinase-signaling pathways (Li and Zafarullah, 1998) . Although the exact mechanisms that mediate the effect of TIMP-3 require further investigations, these data have important implications for understanding the relation between the MMP-2 downregulation-induced apoptosis via TIMP-3. The majority of clinical trials using synthetic MMP inhibitors have proven to be disappointing, principally owing to lack of efficacy and untoward side effects . However, survival benefits in some trials in pancreatic (Evans et al., 2001 ) and gastric cancer (Bramhall et al., 2002) are indicative of the clinical value of MMP inhibition, and the basic principle of therapeutic MMP inhibition remains intact. In this context, our study demonstrates that siRNA-mediated targeting of MMP-2 could have significant therapeutic value over small molecule inhibitors due to two reasons. We show that Ad-MMP-2 infection specifically inhibits MMP-2 and TIMP-3 in lung cancer C Chetty et al MMP-2 expression reducing the local proteolysis, and induced TIMP-3 expression whose biological characteristics have also been exploited in cancer gene therapy. 
Materials and methods
Antibodies and reagents
Adenoviral siRNA constructs and infection
The adenoviral siRNA for MMP-2 (Ad-MMP-2) and Ad-SV were constructed and amplified as described by us previously (Chetty et al., 2006) . Viral titers were quantified as pfu/ml following infection of 293 cells. Titers were obtained for the viruses used in this work are Ad-SV (7.6 Â 10 11 pfu/ml) and Ad-MMP-2 (5.0 Â 10 11 ). The amount of infective adenoviral vector per cell (pfu/cell) in culture media was expressed as MOI. Virus constructs were diluted in serum-free culture media to the desired concentration and added to cells and incubated at 371C for 1 h. The necessary amount of complete medium was then added and cells were incubated for the desired time periods.
Immunoblot analysis A549 lung cancer cells were infected with mock, 100 MOI of Ad-SV or the indicated MOI of Ad-MMP-2 for 48 h. Whole cell lysates were by lysing cells in RIPA buffer as described by us previously (Chetty et al., 2006) . For tissue samples, the frozen tissue (B0.2 g) were ground to a powder with liquid nitrogen and homogenized in 1 ml of RIPA buffer, kept on ice for 15 min, centrifuged at 13 500 r.p.m. for 20 min at 41C and supernatants were collected. Equal concentration of protein were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene fluoride membrane according to the manufacturer's instructions. After blocking with 5% non-fat dry milk and 0.1% Tween-20 in PBS, membranes were incubated with 1:1000 dilution of primary antibodies and horseradish peroxidase conjugate secondary antibodies were used to detect chemiluminescent signals using the ECL system. GAPDH levels served as loading control.
Animal experiments
Animal experiments were performed as described previously (Chetty et al., 2006) . Subcutaneous tumors were either frozen immediately at À801C or fixed in 10% phosphate-buffered formaldehyde.
Statistical analysis
Results were analysed using a two-tailed Student's t-test to assess statistical significance. Values of Po0.05 were considered statistically significant.
